Tagged with B

Romania Cătălin Radu of Bristol Myers Squibb (BMS) Romania explains how the Celgene acquisition is allowing the company to provide their expertise on a larger scale. He reveals how BMS has become Romanian market leader in immuno-oncology by launching new indications and therapy lines for its products in the country. He…

Belgium Chantal Depondt, president of the Belgian Neurological Society (BNS), introduces the mission of the professional association and offers her insights into the healthcare and research dynamics surrounding neurological diseases. Depondt also delivers a clear message about the importance of continued public and private investments in basic research to foster new…

Romania Cecilia Radu of Novo Nordisk Romania shares her tumultuous four years that have seen declining market share and have culminated in launching the company’s first new product onto the market in several years. She reveals that the perception of diabetes in Romania is skewed, as more than 50 percent of…

Belgium Javier Aracil, country manager of Allergan in Belgium and Luxembourg, introduces the priorities and objectives as he set as he entered his first country manager position coming from holding key international positions in commercial, pricing, and market access within the company. As a newcomer to Belgium, Aracil highlights the particularities…

Romania Attila Fejer general manager of Eli Lilly in Romania gives his insights on the “deadly cocktail” of challenging policies that govern the pharmaceutical industry in the country. He shares the new therapeutic direction that Lilly has taken by moving into rheumatology and dermatology. Additionally, he points to the change in…

Belgium Isabelle De Walsche, managing director of Gedeon Richter in Belgium, the Netherlands, and Luxembourg gives an update on the affiliate’s development since its establishment in 2012. De Waslche goes on to speak about the unique cluster dynamic which comes with managing the three markets and also highlights her priorities to…

Czech Republic Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or innovative therapies facing significant delays before being able to enter the market.   While the timelines are still outside the defined framework, the situation is much…

Czech Republic A cross-industry push for better and broader access to innovative treatments is underway in the Czech Republic. Ripe for reform is the country’s orphan drug legislation as no standard pathway for their assessment, pricing and reimbursement currently exists.   [For cancer treatment the country has been] quite successful in moving…

Belgium In its ruling of 30 January 2020, the Court of Justice of the European Union (‘CJEU’) has clarified for the first time the criteria governing whether a reverse payment settlement agreement concerning a dispute between the holder of a pharmaceutical patent (‘originator’) and a manufacturer of generic medicines (‘generic’) is…

Coronavirus Chinese biotech Clover Biopharmaceuticals may have flown under the radar thus far but it has stepped into the global limelight recently by partnering with GSK to develop a vaccine from the novel coronavirus, COVID-19, now wreaking havoc around the world. But who exactly are the brains behind Clover Biopharmaceuticals and…

Czech Republic Jiří Lukeš, of B Braun Czech Republic, introduces the success of the affiliate he helped establish over 27 years ago, and why he feels that the local business is doing considerably better than counterparts in neighbouring CEE countries. Moreover, Lukeš shares the focus of the business, moving away from being…

Global Greg Reh leads Deloitte’s global life sciences sector which includes clients in biopharma, medtech, generics and distribution businesses, as well as non-profit patient advocacy organizations and regulatory agencies. He discusses talent acquisition and retention in global life sciences today, the challenges around data and AI uptake, and the future of…